Cullinan Therapeutics Inc’s filing revealed that its Chief Scientific Officer Michaelson Jennifer unloaded Company’s shares for reported $50040.0 on Jan 06 ’25. In the deal valued at $12.51 per share,4,000 shares were sold. As a result of this transaction, Michaelson Jennifer now holds 95,760 shares worth roughly $0.96 million.
Then, JENNIFER MICHAELSON bought 8,000 shares, generating $101,440 in total proceeds.
Before that, AHMED NADIM sold 8,400 shares. Cullinan Therapeutics Inc shares valued at $99,708 were divested by the President and CEO at a price of $11.87 per share. As a result of the transaction, AHMED NADIM now holds 263,150 shares, worth roughly $2.63 million.
UBS initiated its Cullinan Therapeutics Inc [CGEM] rating to a Buy in a research note published on October 24, 2024; the price target was $30. A number of analysts have revised their coverage, including Stifel’s analysts, who began to cover the stock in early May with a ‘”a Buy”‘ rating. William Blair began covering CGEM with “an Outperform” recommendation on April 15, 2024. Wedbush started covering the stock on February 15, 2024. It rated CGEM as “an Outperform”.
Price Performance Review of CGEM
On Tuesday, Cullinan Therapeutics Inc [NASDAQ:CGEM] saw its stock fall -9.33% to $10.01. Over the last five days, the stock has lost -15.03%. Cullinan Therapeutics Inc shares have fallen nearly -17.82% since the year began. Nevertheless, the stocks have fallen -3.84% over the past one year. While a 52-week high of $30.19 was reached on 01/03/25, a 52-week low of $10.02 was recorded on 01/14/25. SMA at 50 days reached $13.07, while 200 days put it at $17.53.
Levels Of Support And Resistance For CGEM Stock
The 24-hour chart illustrates a support level at 9.24, which if violated will result in even more drops to 8.46. On the upside, there is a resistance level at 11.05. A further resistance level may holdings at 12.08. The Relative Strength Index (RSI) on the 14-day chart is 30.66, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.05, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 85.38%. Stochastics %K at 21.94% indicates the stock is a holding.
How much short interest is there in Cullinan Therapeutics Inc?
A steep rise in short interest was recorded in Cullinan Therapeutics Inc stocks on 2024-12-31, growing by 0.66 million shares to a total of 9.82 million shares. Yahoo Finance data shows the prior-month short interest on 2024-11-29 was 9.16 million shares. There was a rise of 6.71%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on June 15, 2023 when TD Cowen began covering the stock and recommended ‘”an Outperform”‘ rating .
